Hematologija

Kaur MN, Arnold DM, Heddle NM, Cook RJ, Hsia C, Blostein M, Jamula E, Sholzberg M, Lin Y, Kassis J, Larratt L, Tinmouth A, Carruthers J, Li N, Liu Y, Xie F

Izvor‎: Blood Adv. 2022;6(3):785-92.

Indeks‎: PubMed 34781363

DOI‎: 10.1182/bloodadvances.2021005627

https://pubmed.ncbi.nlm.nih.gov/34781363/ (otvara se novi prozor)

Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. (otvara se novi prozor)

Leahy MF, Trentino KM, May C, Swain SG, Chuah H, Farmer SL.

Izvor‎: Transfusion 2017;57(9):2189-96.

Indeks‎: PubMed 28671296

DOI‎: 10.1111/trf.14191

https://www.ncbi.nlm.nih.gov/pubmed/28671296 (otvara se novi prozor)

Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation. (otvara se novi prozor)

Lightdale JR, Randolph AG, Tran CM, Jiang H, Colon A, Houlahan K, Billet A, Sloan S, Lehmann LE.

Izvor‎: Biol Blood Marrow Transplant 2012;18(5):813-7.

Indeks‎: PubMed 22080050

DOI‎: 10.1016/j.bbmt.2011.10.043

https://www.ncbi.nlm.nih.gov/pubmed/22080050 (otvara se novi prozor)

The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costing. (otvara se novi prozor)

McQuilten ZK, Higgins AM, Burns K, Chunilal S, Dunstan T, Haysom HE, Kaplan Z, Rushford K, Saxby K, Tahiri R, Waters N, Wood EM.

Izvor‎: Transfusion 2019;59(11):3386-95.

Indeks‎: PubMed 31664712

DOI‎: 10.1111/trf.15558

https://www.ncbi.nlm.nih.gov/pubmed/31664712 (otvara se novi prozor)

Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (otvara se novi prozor)

Mehra T, Seifert B, Bravo-Reiter S, Wanner G, Dutkowski P, Holubec T, Moos RM, Volbracht J, Manz MG, Spahn DR

Izvor‎: Transfusion 2015;55(12):2807-15.

Indeks‎: PubMed 26264557

DOI‎: 10.1111/trf.13260

https://www.ncbi.nlm.nih.gov/pubmed/26264557 (otvara se novi prozor)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (otvara se novi prozor)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Izvor‎: Cancer 2013;119(1):107-14.

Indeks‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (otvara se novi prozor)

Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece. (otvara se novi prozor)

Nikolaidi E, Hatzikou M, Geitona M.

Izvor‎: Cost Eff Resour Alloc 2013;11(1):16.

Indeks‎: PubMed 23870502

DOI‎: 10.1186/1478-7547-11-16

https://www.ncbi.nlm.nih.gov/pubmed/23870502 (otvara se novi prozor)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (otvara se novi prozor)

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Izvor‎: Support Care Cancer 2012;20(1):159-65.

Indeks‎: PubMed 21359879

DOI‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 (otvara se novi prozor)

Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada. (otvara se novi prozor)

Pettigrew M, Garces K, Deuson R, Kassis J, Laroche V

Izvor‎: J Med Econ 2013;16(2):318-26.

Indeks‎: PubMed 23216012

DOI‎: 10.3111/13696998.2012.756400

https://www.ncbi.nlm.nih.gov/pubmed/23216012 (otvara se novi prozor)

Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. (otvara se novi prozor)

Ravangard R, Mirzaei Z, Keshavarz K, Haghpanah S, Karimi M.

Izvor‎: Hematology 2018;23(7):417-22.

Indeks‎: PubMed 29157136

DOI‎: 10.1080/10245332.2017.1404262

https://www.ncbi.nlm.nih.gov/pubmed/29157136 (otvara se novi prozor)

The burden of blood transfusion: a utilization and economic analysis--a pilot study in patients with chemotherapy-induced anemia (CIA). (otvara se novi prozor)

Reitan JF, Kudrik FJ, Fox K, van Breda A, Shreay S, Corey-Lisle PK.

Izvor‎: J Med Econ 2013;16(5):633-8.

Indeks‎: PubMed 23425291

DOI‎: 10.3111/13696998.2013.778269

https://www.ncbi.nlm.nih.gov/pubmed/23425291 (otvara se novi prozor)

Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. (otvara se novi prozor)

Sarode R, Refaai MA, Matevosyan K, Burner JD, Hampton S, Rutherford C.

Izvor‎: Transfusion 2010;50(2):487-92.

Indeks‎: PubMed 19804569

DOI‎: 10.1111/j.1537-2995.2009.02413.x

https://www.ncbi.nlm.nih.gov/pubmed/19804569 (otvara se novi prozor)

Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. (otvara se novi prozor)

Stallworth JR, Jerrell JM, Tripathi A.

Izvor‎: Am J Hematol 2010;85(10):795-7.

Indeks‎: PubMed 20645429

DOI‎: 10.1002/ajh.21772

https://www.ncbi.nlm.nih.gov/pubmed/20645429 (otvara se novi prozor)

Increased hospital costs associated with red blood cell transfusion. (otvara se novi prozor)

Trentino KM, Farmer SL, Swain SG, Burrows SA, Hofmann A, Ienco R, Pavey W, Daly FF, Van Niekerk A, Webb SA, Towler S, Leahy MF.

Izvor‎: Transfusion 2015;55(5):1082-9.

Indeks‎: PubMed 25488623

DOI‎: 10.1111/trf.12958

https://www.ncbi.nlm.nih.gov/pubmed/25488623 (otvara se novi prozor)

ALTERNATIVE TRANSFUZIJI KRVI I FINANCIJSKA ISPLATIVOST

Hematologija

hrvatski

Hematologija

https://assetsnffrgf-a.akamaihd.net/assets/ct/1add6d1d93/images/syn_placeholder_sqr.png

Early intravenous iron administration in the Emergency Department reduces red blood cell unit transfusion, hospitalisation, re-transfusion, length of stay and costs. (otvara se novi prozor)

Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (otvara se novi prozor)

Restrictive blood transfusion practices are associated with improved patient outcomes. (otvara se novi prozor)

Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom. (otvara se novi prozor)

Recombinant activated factor VII use in critically ill infants with active hemorrhage. (otvara se novi prozor)

Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. (otvara se novi prozor)

Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. (otvara se novi prozor)

Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation. (otvara se novi prozor)

The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costing. (otvara se novi prozor)

Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (otvara se novi prozor)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (otvara se novi prozor)

Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece. (otvara se novi prozor)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (otvara se novi prozor)

Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada. (otvara se novi prozor)

Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. (otvara se novi prozor)

The burden of blood transfusion: a utilization and economic analysis--a pilot study in patients with chemotherapy-induced anemia (CIA). (otvara se novi prozor)

Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. (otvara se novi prozor)

Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. (otvara se novi prozor)

Increased hospital costs associated with red blood cell transfusion. (otvara se novi prozor)

Odbor za kontaktiranje s bolnicama (OKB)

Preuzmite medicinske informacije

Filmovi

Hematologija

Izaberi svoj jezik

Podijeli